Journal of Controlled Release

Dual-transporter-targeted oral semaglutide nanomicelles enable enhanced intestinal absorption and metabolic reprogramming in obesity and diabetes

By Laxman Subedi, Arjun Dhwoj Bamjan, Eunbin Kim, Jin Woo Park

Experiments in animalsInterventions

The paper

Laxman Subedi, Arjun Dhwoj Bamjan, Eunbin Kim, Jin Woo Park

Mokpo National University

Journal of Controlled Release, 24 Aug 2026

doi.org/10.1016/j.jconrel.2026.115297 PubMed 42636888

The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Nature Medicine4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Research Square8 Oct 2026
Semaglutide improved heart artery function in pigs